New hope for Tough-to-Treat breast cancer? drug combo trial aims to shrink tumors before surgery
NCT ID NCT04872985
Summary
This study is testing if adding an oral drug called pyrotinib to standard chemotherapy before surgery is more effective for a specific type of breast cancer. It involves 140 women with stage II-III, hormone-positive, HER2-negative breast cancer that has high levels of a protein called HER4. Participants are randomly assigned to receive either the real drug or a placebo pill alongside their chemo to see which leads to better tumor shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Guangzhou, Guangdong, 510120, China
Conditions
Explore the condition pages connected to this study.